Craft

Advanced
  • Home
  •  / Revolution Medicines
Revolution Medicines

Revolution Medicines

Stock Price

$50.4

2024-10-29

Market Capitalization

$8.4 B

2024-10-29

Revenue

$11.6 M

FY, 2023

Revolution Medicines Summary

Company Summary

Overview
Revolution Medicines (RevMed) is a clinical-stage oncology company that develops therapies for cancer patients. It discovers and delivers drugs for patients living with renal artery stenosis (RAS)-addicted cancer.
Type
Public
Status
Active
Founded
2014
HQ
Redwood City, CA, US | view all locations
Website
https://www.revmed.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Mark A. Goldsmith

    Mark A. Goldsmith, President, Chief Executive Officer and Board Chairman

  • Steve Kelsey

    Steve Kelsey, President, Research and Development

  • Luan M. Wilfong

    Luan M. Wilfong, Chief Human Resources Officer

  • Adrian Gill

    Adrian Gill, Executive Vice President and Head, Early Discovery

Operating MetricsView all

Facility Space Leased, sq. ft.

164.8K
32.9%

FY, 2023

LocationsView all

2 locations detected

  • Redwood City, CA HQ

    United States

    700 Saginaw Drive

  • Redwood City, CA

    United States

    800 Saginaw Drive

Revolution Medicines Financials

Summary Financials

Net income (Q1, 2026)
($453.8M)
Cash (Q1, 2026)
$440.9M
EBIT (Q1, 2026)
($445.2M)
Enterprise value
$8.1B

Competitors and Similar Companies

Compare competitors

Footer menu

Product

Solutions

Resources

Company

© Craft.co 2026
Share price data provided by IEX